Clinical Trials
Breast Cancer
Adjuvant Breast Cancer
3144A2-3004-WW
A Randomized Double-Blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.
-
Principal Investigator: Thomas M. Cosgriff, MD, FACP
Metastatic Breast Cancer
CDX011-03
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients with Advanced GPNMB-expressing Breast Cancer.
- Prinipal Investigator: Milton W. Seiler, MD
3144A2-3005-WW
A Phase III, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment For ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer.
- Principal Investigator:Thomas M. Cosgriff, MD, FACP
TDM 4370g
A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM 1 vs Capecitabine + Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Who have received Prior Trastuzumab- Based Therapy.
- Principal Investigator: Thomas M. Cosgriff, MD, FACP
